By adding an ACE inhibitor or ARB to the thiazide, an additive BP-lowering effect may be Use of combination therapy may also improve adherence. Several 2- and 3-fixed-dose drug combinations of antihypertensive drug therapy are available, with complemen- tary mechanisms of action among the components (Online Data Supplement D). However, it should be noted that many triple-dose combinations may contain a lower-than-optimal dose of thiazide diuretic. Table 18 is a summary of oral antihypertensive drugs. Recommendation-Specific Supportive Text 1. Drug combinations that have similar mechanisms of ac- tion or clinical effects should be avoided. For example, 2 drugs from the same class should not be administered together (eg, 2 different beta blockers, ACE inhibitors, or nondihydropyridine CCBs). Likewise, 2 drugs from classes that target the same BP control system are less effective and potentially harmful when used together (eg, ACE inhibitors, ARBs). Exceptions to this rule in- clude concomitant use of a thiazide diuretic, K-sparing diuretic, and/or loop diuretic in various combinations. Also, dihydropyridine and nondihydropyridine CCBs can be combined. High-quality RCT data demonstrate that simultaneous administration of RAS blockers (ie, ACE inhibitor with ARB; ACE inhibitor or ARB with renin inhibitor aliskiren) increases cardiovascular and renal 8.1.5. BP Goal for Patients With Hypertension Recommendations for BP Goal for Patients With Hypertension References that support recommendations are summarized in Online Data Supplement 26 and Systematic Review Report. COR LOE Recommendations I SBP: B-RSR 1. For adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher (see Section 8.1.2), a BP target of less than 130/80 mm Hg is DBP: C-EO IIb SBP: B-NR 2. 